To investigate the prognostic and immune values of ferredoxin 1 (FDX1) in brain lower grade glioma (LGG). Data from the Cancer Gene Atlas Database and the Genotype and Gene Expression Correlation Database were collected to compare the expression difference of FDX1 between glioma tissues and normal tissues, along with immunohistochemical method. Cox regression analysis was used to evaluate the relationship between FDX1 expression and survival indicators. The Kaplan–Meier method was used to assess independent risk of FDX1 in LGG survival probability. The Tumor Immune Estimation Resource database was used to evaluate the correlation between FDX1 expression and immune cell infiltration. FDX1 was overexpressed in LGG than normal tissues. The Kaplan–Meier analysis showed high FDX1 expression was significantly correlated with poor overall survival, disease specific survival and progress free interval (P < 0.001). A positive correlation was found between FDX1 expression and infiltration of B cells, CD4+ T cells, CD8+ T cells, macrophages, neutrophils and dendritic cells. FDX1 was positively correlated with immune checkpoints in LGG. FDX1 may serve as a specific prognostic and therapeutic biomarker for LGG.